Alessandra Bulotta

Alessandra Bulotta
申请预约
专科:
肿瘤科
职业:
肿瘤科医生
医疗机构:
临床肿瘤科 @ 圣拉斐尔科学研究医院
语言:
EN
EN
IT
IT
申请预约

个人简介

Dr. Alessandra Bulotta is an oncologist at the Medical Oncology Unit of IRCCS Ospedale San Raffaele, directed by Professor Stefano Cascinu.

She graduated in Medicine and Surgery in 2004 from the University Magna Græcia of Catanzaro, where she also specialized in Medical Oncology in 2009.

Dr. Bulotta is responsible for the Thoracic Neoplasms Unit and Cutaneous and Melanoma Tumors, managing patients with these conditions in both hospital and outpatient settings. She coordinates the multidisciplinary team dedicated to the treatment and care of patients with thoracic tumors and the Molecular Tumor Board. She is also a member of the multidisciplinary team for the treatment and care of patients with malignant melanoma and non-melanoma skin tumors, and is involved in the workgroup for the planning of diagnostic and therapeutic pathways (PDTA). Additionally, she plays an active role in the organizational workgroup for accrediting Ospedale San Raffaele as a Comprehensive Cancer Center (CCC).

Currently, she is the Principal Investigator in phase II and phase III clinical trials involving drugs for the treatment of lung cancer and melanoma. Her research interests include the biology of lung neoplasms, predictive markers for therapy response, and new anticancer agents.

Dr. Bulotta is an author and co-author of numerous publications and regularly participates in national and international congresses in her field.

教育背景

Magna Græcia University of Catanzaro
Degree in Medicine and Surgery - 2004

Magna Græcia University of Catanzaro
Specialization in Medical Oncology - 2009

您需要预约吗？

联系我们，我们将为您妥善安排。
申请预约

出版物

最新出版物

Second-line therapy of squamous non-small cell lung cancer: an evolving landscape.
Expert Rev Respir Med. 2017 Jun;11(6):469-479. doi: 10.1080/17476348.2017.1326822. Epub 2017 May 15.
Lazzari C, Karachaliou N, Gregorc V, Bulotta A, Gonzalez-Cao M, Verlicchi A, Altavilla G, Rosell R, Santarpia M.
Combination of immunotherapy with chemotherapy and radiotherapy in lung cancer: is this the beginning of the end for cancer?
Ther Adv Med Oncol. 2018 Apr 6;10:1758835918762094.
Lazzari C, Karachaliou N, Bulotta A, Viganó M, Mirabile A, Brioschi E, Santarpia M, Gianni L, Rosell R, Gregorc V.
Efficacy of ALK inhibitors on NSCLC brain metastases: A systematic review and pooled analysis of 21 studies PLoS One.
2018 Jul 27;13(7):e0201425. doi: 10.1371/journal.pone.0201425. eCollection 2018.
Petrelli F, Lazzari C, Ardito R, Borgonovo K, Bulotta A, Conti B, Cabiddu M, Capitanio JF, Brighenti M, Ghilardi M, Gianni L, Barni S, Gregorc V.
Combined exosomal RNA and circulating tumor DNA for epidermal growth factor mutation detection in non-small cell lung cancer.
J Thorac Dis. 2018 Nov;10(Suppl 33):S4023-S4027. doi: 10.21037/jtd.2018.10.17.
Lazzari C, Gregorc V, Cangi MG, Giovannetti E, Bulotta A, Santarpia M.
Identification and monitoring of somatic mutations in circulating cell-free tumor DNA in lung cancer patients.
Lung Cancer. 2019 Aug;134:225-232. doi: 10.1016/j.lungcan.2019.06.010. Epub 2019 Jun 11.
Francaviglia I, Magliacane G, Lazzari C, Grassini G, Brunetto E, Dal Cin E, Girlando S, Medicina D, Smart CE, Bulotta A, Gregorc V, Pecciarini L, Doglioni C, Cangi MG.
Temozolomide in combination with either veliparib or placebo in patients with relapsed-sensitive or refractory small-cell lung cancer.
Transl Lung Cancer Res. 2018 Dec;7(Suppl 4):S329-S333. doi: 10.21037/tlcr.2018.12.02.
Lazzari C, Gregorc V, Bulotta A, Dottore A, Altavilla G, Santarpia M.
PD-1 Inhibitors-Related Neurological Toxicities in Patients with Non-Small-Cell Lung Cancer: A Literature Review.
Cancers (Basel). 2019 Mar 1;11(3). pii: E296. doi: 10.3390/cancers11030296. Review.
Mirabile A, Brioschi E, Ducceschi M, Piva S, Lazzari C, Bulotta A, Viganò MG, Petrella G, Gianni L, Gregorc V.
Immunohistochemical Evaluation and Clinicopathological Correlation of Mer and Axl Tyrosine Kinase TAM Receptors in Cutaneous Melanoma.
Dermatol Pract Concept. 2020 Apr 3;10(2):e2020029. doi: 10.5826/dpc.1002a29. eCollection 2020. PMID: 32363092
Pontara A, Paolino G, Gregorc V, Mercuri SR, Bulotta A, Bearzi P, Doglioni C, Rizzo N.
Spontaneous Regression of Primary Melanoma and Multiple Melanocytic Nevi in a Patient With Metastatic Melanoma.
Dermatol Pract Concept. 2020 Jun 29;10(3):e2020052. doi: 10.5826/dpc.1003a52. eCollection 2020 Jul. PMID: 32685272
Paolino G, Rizzo N, Pampena R, Bearzi P, Bulotta A, Gregorc V, Brianti P, Moliterni E, Mercuri SR.
Clinicopathological and dermoscopic features of amelanotic and hypomelanotic melanoma: a retrospective multicentric study.
Int J Dermatol. 2020 Jul 29. doi: 10.1111/ijd.15064. Online ahead of print. PMID: 32726478
Paolino G, Bearzi P, Pampena R, Longo C, Frascione P, Rizzo N, Raucci M, Carbone A, Cantisani C, Ricci F, Didona D, Frattini F, Bulotta A, Gregorc V, Mercuri SR.
Intratumoral Cellular Heterogeneity: Implications for Drug Resistance in Patients with Non-Small Cell Lung Cancer.
Cancers (Basel). 2021 Apr 22;13(9):2023. doi: 10.3390/cancers13092023.
Gregorc V, Lazzari C, Mandalá M, Ippati S, Bulotta A, Cangi MG, Khater A, Viganò MG, Mirabile A, Pecciarini L, Ogliari FR, Arrigoni G, Grassini G, Veronesi G, Doglioni C.
History of Extensive Disease Small Cell Lung Cancer Treatment: Time to Raise the Bar? A Review of the Literature.
Cancers (Basel). 2021 Feb 27;13(5):998. doi: 10.3390/cancers13050998.
Lazzari C, Mirabile A, Bulotta A, Viganó MG, Ogliari FR, Ippati S, DellOca I, Santarpia M, Lorusso V, Reck M, Gregorc V.
Next Generation Sequencing in Non-Small Cell Lung Cancer: Pitfalls and Opportunities.
Diagnostics (Basel). 2020 Dec 15;10(12):1092. doi: 10.3390/diagnostics10121092.
Lazzari C, Bulotta A, Cangi MG, Bucci G, Pecciarini L, Bonfiglio S, Lorusso V, Ippati S, Arrigoni G, Grassini G, Doglioni C, Gregorc V.
Eruptive cherry angiomas and uveal melanoma: beyond a simple association.
Clin Exp Dermatol. 2021 Jul;46(5):946-948. doi: 10.1111/ced.14609. Epub 2021 May 12.
Paolino G, Cicinelli MV, Brianti P, Prezioso C, Bulotta A, Rizzo N, Bandello F, Lugini L, Federici C, Gregorc V, Modorati GM, Mercuri SR.
Role of stereotactic radiosurgery for the treatment of brain metastasis in the era of immunotherapy: A systematic review on current evidences and predicting factors.
Crit Rev Oncol Hematol. 2021 Sep;165:103431. doi: 10.1016/j.critrevonc.2021.103431. Epub 2021 Jul 27. Review.
Gagliardi F, De Domenico P, Snider S, Roncelli F, Pompeo E, Barzaghi LR, Bulotta A, Gregorc V, Lazzari C, Cascinu S, Finocchiaro G, Mortini P.
Tocilizumab for the treatment of immune-related adverse events: a systematic literature review and a multicentre case series.
Eur J Intern Med. 2021 Aug 11:S0953-6205(21)00266-1. doi: 10.1016/j.ejim.2021.07.016.
Campochiaro C, Farina N, Tomelleri A, Ferrara R, Lazzari C, De Luca G, Bulotta A, Signorelli D, Palmisano A, Vignale D, Peretto G, Sala S, Esposito A, Garassino M, Gregorc V, Dagna L.
Angiogenesis inhibition in lung cancer: emerging novel strategies.
Curr Opin Oncol. 2022 Jan 1;34(1):107-114. doi: 10.1097/CCO.0000000000000807. PMID: 34812193 Review.
Lazzari C, Bulotta A, Damiano G, Mirabile A, Viganó M, Veronesi G, Gregorc V.
Autoantibody positivity predicts severity of rheumatic immune-related adverse events to immune-checkpoint inhibitors.
Eur J Intern Med. 2022 Sep; 103:95-99. doi: 10.1016/j.ejim.2022.07.005. Epub 2022 Jul 9.PMID: 3582119
Campochiaro C, Farina N, Tomelleri A, Ferrara R, Viola S, Lazzari C, De Luca G, Raggi D, Bulotta A, Matucci-Cerinic M, Necchi A, Garassino M, Gregorc V, Dagna L. 2

您需要预约吗？

联系我们，我们将为您妥善安排。
申请预约